Personal information

Emails & domains

Verified email domains

Other IDs

Loop profile: 1931454

Countries

United Kingdom

Activities

Collapse all

Employment (4)

AstraZeneca: Cambridge, GB

2023-07-10 to present | Senior Scientist (Early Oncology, DMPK)
Employment
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

University of Manchester: Manchester, GB

2021-05 to 2023-07 | Postdoc Research Associate (Faculty of Biology Medicine and Health, Division of Pharmacy and Optometry)
Employment
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

Eli Lilly (United Kingdom): Windlesham, Windlesham, GB

2017-02 to 2017-08 | Behavioural and electrophysilogical studies on mice taupathy models (In vivo neurophysiology)
Employment
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

Theageneio General Hospital: Thessaloniki, GR

2016-04 to 2016-07 | Diagnosis of haematological diseases using Flow cytometry (Haematology)
Employment
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

Education and qualifications (4)

The University of Manchester Faculty of Biology Medicine and Health: Manchester, Greater Manchester, GB

2018-01 to 2021-03 | PhD in Pharmacy and Pharmaceutical Sciences (Pharmacy)
Education
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

King's College London: London, London, GB

2016-09 to 2017-08 | MSc in Drug Discovery Skills (Pharmacy and Pharmacology)
Education
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

Aristotle University of Thessaloniki School of Biology: Thessaloniki, GR

2012-09 to 2016-07 | BSc in Biology (Biology)
Education
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

Université de Rennes 1: Rennes, Bretagne, FR

2014-08 to 2015-01 | Erasmus student (Sciences de la vie et de l'environment)
Education
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

Works (12)

The quest to define cancer-specific systems parameters for personalized dosing in oncology

Expert Opinion on Drug Metabolism & Toxicology
2025-03-24 | Journal article
DOI: 10.1080/17425255.2025.2476560
Contributors: Areti-Maria Vasilogianni; Brahim Achour; Zubida M. Al-Majdoub; Sheila Annie Peters; Jill Barber; Amin Rostami-Hodjegan
Source: check_circle
Crossref

Complementarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transporters in human liver

Molecular Omics
2024-02-19 | Journal article | Author
DOI: 10.1039/d3mo00144j
SOURCE-WORK-ID:

d8b4deea-abc7-44e0-b998-cc5b9c4524d3

EID:

2-s2.0-85178280803

PMID: 37975521
Contributors: ARETI MARIA VASILOGIANNI; Sarah Alrubia; Eman El-Khateeb; Zubida M. Al-Majdoub; Narciso Couto; Brahim Achour; Amin Rostami-Hodjegana; Jill Barber
Source: check_circle
University of Manchester - PURE
grade
Preferred source (of 2)‎

Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis

Frontiers in Oncology
2023-02-20 | Journal article
DOI: 10.3389/fonc.2023.1010563
Part of ISSN: 2234-943X
Contributors: Areti-Maria Vasilogianni; Zubida M. Al-Majdoub; Brahim Achour; Sheila Annie Peters; Amin Rostami-Hodjegan; Jill Barber
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

Label-Free but Still Constrained: Assessment of Global Proteomic Strategies for the Quantification of Hepatic Enzymes and Transporters

Drug Metabolism and Disposition
2022-06 | Journal article
DOI: 10.1124/dmd.121.000780
Contributors: Jill Barber; Zubida M. Al-Majdoub; Narciso Couto; Areti-Maria Vasilogianni; Annika Tillmann; Sarah Alrubia; Amin Rostami-Hodjegan; Brahim Achour
Source: check_circle
Crossref

Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease

Journal of Proteomics
2022-05 | Journal article
DOI: 10.1016/j.jprot.2022.104601
Part of ISSN: 1874-3919
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

Quantitative Proteomics of Hepatic Drug‐Metabolizing Enzymes and Transporters in Patients with Colorectal Cancer Metastasis

Clinical Pharmacology & Therapeutics
2022-05-03 | Journal article
DOI: 10.1002/cpt.2633
Part of ISSN: 0009-9236
Part of ISSN: 1532-6535
Source: Self-asserted source
ARETI MARIA VASILOGIANNI

Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects

British Journal of Clinical Pharmacology
2022-04 | Journal article
DOI: 10.1111/bcp.15098
Contributors: Areti‐Maria Vasilogianni; Zubida M. Al‐Majdoub; Brahim Achour; Sheila Annie Peters; Amin Rostami‐Hodjegan; Jill Barber
Source: check_circle
Crossref

A family of QconCATs (Quantification conCATemers) for the quantification of human pharmacological target proteins

Journal of Proteomics
2022-03 | Journal article
DOI: 10.1016/j.jprot.2022.104572
Part of ISSN: 1874-3919
Source: Self-asserted source
ARETI MARIA VASILOGIANNI
grade
Preferred source (of 2)‎

Hepatic Scaling Factors for In Vitro-In Vivo Extrapolation (IVIVE) of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis

Drug Metabolism and Disposition
2021-05-12 | Journal article
DOI: 10.1124/dmd.121.000359
Contributors: Areti-Maria Vasilogianni; Brahim Achour; Daniel Scotcher; Sheila Annie Peters; Zubida M. Al-Majdoub; Jill Barber; Amin Rostami-Hodjegan
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Toxicity assessment and comparison of the land snail's Cornu aspersum responses against CuO nanoparticles and ZnO nanoparticles

Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology
2020-10 | Journal article
DOI: 10.1016/j.cbpc.2020.108817
Part of ISSN: 1532-0456
Source: Self-asserted source
ARETI MARIA VASILOGIANNI
grade
Preferred source (of 2)‎

Mass Spectrometry‐Based Abundance Atlas of ABC Transporters in Human Liver, Gut, Kidney, Brain, and Skin

FEBS Letters
2020-10-31 | Journal article
DOI: 10.1002/1873-3468.13982
Part of ISSN: 0014-5793
Part of ISSN: 1873-3468
Source: Self-asserted source
ARETI MARIA VASILOGIANNI
grade
Preferred source (of 3)‎

Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice.

Pharmacology & therapeutics
2019-07 | Journal article
DOI: 10.1016/j.pharmthera.2019.107397
PMID: 31376433
Contributors: El-Khateeb E; Vasilogianni AM; Alrubia S; Al-Majdoub ZM; Couto N; Howard M; Barber J; Rostami-Hodjegan A; Achour B
Source: Self-asserted source
ARETI MARIA VASILOGIANNI via Europe PubMed Central
grade
Preferred source (of 2)‎

Peer review (2 reviews for 1 publication/grant)

Review activity for Biopharmaceutics & drug disposition. (2)
How many people are using ORCID?